Both sunitinib and sorafenib prevent tumor angiogenesis, tumor growth and metastasis by inhibiting receptors of VEGF and PDGF (Bergers et al. 2003; Escudier et al. 2012). The gene discussed is VEGFA; the disease is neoplasm.